Entasis Therap Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ENTASIS THERAP, and when can generic versions of ENTASIS THERAP drugs launch?
ENTASIS THERAP has one approved drug.
There are four US patents protecting ENTASIS THERAP drugs.
There are sixty-eight patent family members on ENTASIS THERAP drugs in forty-two countries.
Summary for Entasis Therap
| International Patents: | 68 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Entasis Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entasis Therap | XACDURO (COPACKAGED) | durlobactam sodium; durlobactam sodium; sulbactam sodium | POWDER;INTRAVENOUS | 216974-001 | May 23, 2023 | RX | Yes | Yes | 9,309,245 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Entasis Therap | XACDURO (COPACKAGED) | durlobactam sodium; durlobactam sodium; sulbactam sodium | POWDER;INTRAVENOUS | 216974-001 | May 23, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Entasis Therap | XACDURO (COPACKAGED) | durlobactam sodium; durlobactam sodium; sulbactam sodium | POWDER;INTRAVENOUS | 216974-001 | May 23, 2023 | RX | Yes | Yes | 9,968,593 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Entasis Therap | XACDURO (COPACKAGED) | durlobactam sodium; durlobactam sodium; sulbactam sodium | POWDER;INTRAVENOUS | 216974-001 | May 23, 2023 | RX | Yes | Yes | 9,623,014 | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
